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Vitamin E refers to a family of compounds that 
is divided into two subgroups, namely tocoph-
erol and tocotrienol. Tocopherol is most com-
monly found in vegetable oils, animal fats and 
nuts, whereas tocotrienol is primarily derived 
from only a few vegetable fats, such as palm 
oil, rice bran, oat, wheat germ and barley [1,2].
Structurally, both tocopherol and tocotrienol 
consist of a chromane ring linked to a 16-car-
bon phytyl side chain (FiguRe 1) [3]. However, 
the difference between tocopherol and tocotri-
enol lies in the saturation of the phytyl chain 
and the degree of methylation of the chromane 
ring. The phytyl side chain of tocopherols is 
fully saturated, unlike that of tocotrienol, which 
contains three trans double bonds. Furthermore, 
the four isomers of tocopherol and tocotrienol 
differ in the number and position of methyl 
groups attached to the chromane head. 
Although tocopherol and tocotrienol share 
similar chemical structures, only tocotrienol 
displays promising anticancer activity. Its tumor 
suppressive effects have been demonstrated in 
many cancer cell lines in vitro, including breast, 
colorectal, pancreatic, gastric, liver, lung and 
prostate cancer [4].
In vivo, tocotrienol solution has been 
used mainly for oral administration or as a 
therapeutic adjuvant. 
Oral intake of tocotrienol led to inhib-
ition of tumorigenesis in B16 murine mela-
noma models [5]. However, this adminis-
tration strategy is limited for therapeutic 
purposes by the fact that oral absorption 
of tocotrienol into the circulation is mostly 
mediated by carrier-transporter systems that 
display saturation and down-regulation as a 
result of exposition to high concentrations of 
tocotrienol [6]. 
The use of tocotrienol in combination 
therapy with chemotherapeutic drugs such as 
celecoxib, tamoxifen and statins resulted in syn-
ergistic antiproliferative effects [7–9]. This thera-
peutic response was more pronounced when 
tocotrienol was administered with drugs that 
have complementary anticancer mechanisms 
of action. 
Tocotrienol has been reported to exert its 
anticancer effects through various mechanisms, 
such as induction of apoptosis, activation of 
p53, decrease of oxidative stress and modulation 
of the Bax/Bcl-2 ratio. It is also able to down-
regulate the expression of the VEGF receptor 
and to block intracellular VEGF signaling, 
leading to inhibition of angiogenesis [3,10,11]. 
Tocotrienol also inhibits numerous enzymes 
related to cancer cell proliferation, such as DNA 
polymerase and telomerase and the NF-kB acti-
vation pathway, thus resulting in the potentia-
tion of apop tosis [3,4,10,11]. This multiplicity of 
anticancer effects therefore makes tocotrienol a 
very promising therapeutic molecule. 
However, the potential of tocotrienol in 
cancer therapy is limited by its inability to 
specifically reach tumors at therapeutic con-
centrations after intravenous administration. 
Given the antiproliferative properties of tocot-
rienol, it is crucial to deliver this therapeutic 
drug specifically to its site of action. In addi-
tion, therapeutic formulation of tocotrienol is 
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complicated by its unfavorable physicochemical 
properties (highly viscous oil, nearly insoluble 
in water and readily oxidized by atmospheric 
oxygen). When administered as a solution, 
tocotrienol has poor bioavailability, regardless 
of the route of administration (parenteral, oral 
or topical) [12]. 
In order to address these problems, various 
delivery strategies have been proposed: inclusion 
of tocotrienol in cyclodextrins, prodrugs and 
emulsions, entrapment in lipid nanoparticles, 
and tumor-targeted vesicles. 
Nontargeted delivery strategies
So far, relatively few strategies have been 
attempted to improve the bioavailability and 
delivery of tocotrienol. They consist of includ-
ing tocotrienol in cyclodextrins, prodrugs 
and emulsions.
Cyclodextrins are cyclic oligosaccharides 
containing six to eight a-d-glucopyranoside 
units attached by a-(1,4) glucosidic bonds. 
Their lipophilic inner cavities and hydrophilic 
outer surfaces can interact with numerous 
guest molecules to form noncovalent inclusion 
complexes. Cyclodextrins have therefore been 
particularly useful in oral drug delivery for 
improving the bioavailability of lipophilic drugs 
by increasing the drug solubility and stability at 
the absorption site (the GI tract) and in formu-
lation [13]. Previous studies have demonstrated 
the improved bioavailability of ketoprofen, gris-
eofulvin and terfenadine drugs by inclusion in 
cyclodextrins. A cyclodextrin formulation of 
itraconazole has been commercialized in the 
USA and Europe [13]. 
In their studies of inclusion of tocotrienol 
in cyclodextrins, Ikeda et al. [14], as well as 
Miyoshi et al. [15], have chosen to use g-cyclo-
dextrin, as it shows the highest water solubility 
among the three existing natural cyclodextrins. 
A tocotrienol-rich fraction (TRF) of rice bran 
containing 0.5% a-tocopherol, 0.4% b-tocoph-
erol, 2.8% g-tocopherol, 0.5% d-tocopherol, 
1.8% a-tocotrienol, 0.4% b-tocotrienol, 65.0% 
g-tocotrienol and 4.6% d-tocotrienol was used 
in these two studies. 
Wistar rats and C57Bl6 mice were sub-
jected to a vitamin E free diet for 28 days, 
before being orally administered with either 
TRF as a solution or enclosed in cyclodex-
trins. Pharmacokinetic studies showed an 
increase of plasma concentration after the oral 
administration of TRF included in cyclodex-
trins. The C
max
 and area under curve values 
in mice receiving the cyclodextrin formula-
tion were approximately 1.4-fold higher than 
those after treatment with TRF solution. In 
addition, Miyoshi et al. demonstrated that the 
mice injected with the cyclodextrin formula-
tion of tocotrienol were less sensible to endo-
toxic shock induced by injection with lethal 
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Figure 1. (A) Tocopherols and (B) tocotrienols.
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amounts of Escherichia coli lipopolysaccha-
ride, compared with the mice having received 
TRF solution [15]. These results suggest that 
the inclusion of tocotrienol in cyclodextrins 
enhance the bioavailability and consequently 
the bioactivity of tocotrienol. 
Another strategy to improve the bioavailabil-
ity of tocotrienol was to produce hydrophilic 
prodrugs of tocotrienol. Water-soluble prodrug 
esters have been widely used for enhancing the 
aqueous solubility of poorly soluble drugs that 
contain a hydroxyl group. Ideally, a prodrug 
is expected to improve aqueous solubility and 
should be rapidly converted to the active drug 
in vivo. It has previously been demonstrated 
that esters of g-tocopherol, which has a pheno-
lic functional group such as tocotrienol, have 
good water solubility and were able to enhance 
plasma and liver availability of tocotrienol after 
intravenous administration in rats, suggesting 
that similar improvements could be observed 
with tocotrienol as well. 
Akaho et al. produced an ester derivative 
of g-tocotrienol, namely 2R-g-tocotrienyl 
N,N-dimethylaminoacetate hydrochloride [16]. 
This ester showed high solubility and stabil-
ity in water and was readily converted into the 
active drug g-tocotrienol by esterases in liver. 
The intravenous administration of this pro-
drug to Sprague–Dawley rats resulted in a rapid 
increase in the liver, heart, plasma and kidney 
levels of g-tocotrienol, thus making prodrugs of 
tocotrienol interesting formulations to enhance 
the drug bioavailability. 
The poor bioavailability of tocotrienol makes 
it particularly suitable for self-emulsifying sys-
tems to enhance its oral bioavailability. The 
stability of drugs in the oil phase is increased 
compared with that of the same drug in aque-
ous solutions. In addition, emulsions also allow 
a sustained release of active drugs, resulting in 
increased efficacy of the treatment. It has been 
previously demonstrated that the droplet sizes 
of the emulsion should be as small as possible 
to increase drug bioavailability. 
Tocomin® 50% dissolved in soybean oil has 
been formulated by Yap and Yuen as self-emul-
sifying systems with the addition of the sur-
factants Tween 80 and labrasol [17]. Tocomin® 
50% consisted of 21.6% g-tocotrienol, 6.4% 
d-tocotrienol, 10.7% a-tocotrienol and 10.9% 
a-tocopherol. These emulsions improved 
the bioavailability of tocotrienol by approxi-
mately two- to three-fold compared with 
that of a nonself-emulsifying formulation in 
human volunteers.
Targeted delivery strategies
Three strategies for the tumor-targeted delivery 
of tocotrienol after intravenous administration 
have been tested so far.
Passive tumor targeting of tocotrienol and 
simvastatin co-encapsulated in lipid nano-
particles has been tested by Ali et al. [18]. Lipid 
nanoparticles are particulate systems that pos-
sess a solid lipid core matrix able to solubilize 
lipophilic drugs. These nanoparticles are able to 
accumulate in tumors, owing to the enhanced 
permeability and retention effect observed for 
all particulate systems. 
The tocotrienol used for this study was a 
tocotrienol-rich fraction of palm oil, consist-
ing of 9.8% a-tocopherol, 27.9% a-tocotrienol, 
41.4% g-tocotrienol and 19.2% d-tocotrienol. 
Simvastatin and TRF were both entrapped 
within the oily compartments of the delivery 
system. In vitro, the nanoparticles of TRF 
and simvastatin were demonstrated to have an 
improved antiproliferative effect against +SA 
breast cancer cell line, compared with refer-
ence a-tocopherol nanoparticles (with IC
50
 
respectively of 0.52 µM and 17.7 µM) [18]. 
Prior to this study, we hypothesized that 
active tumor targeting of tocotrienol by entrap-
ment within transferrin-bearing vesicles could 
result in a selective delivery of tocotrienol to 
tumors after intravenous administration, thus 
resulting in an improved therapeutic efficacy. 
Transferrin has been chosen as an active tar-
geting moiety, since transferrin receptors are 
overexpressed in numerous cancers. It was 
hoped that the combination of active target-
ing, based on the use of ligands, and passive 
targeting, based on the accumulation of par-
ticulate delivery systems owing to enhanced 
permeability and retention, would provide a 
tumor-selective targeting strategy for tocotri-
enol delivery. Transferrin has previously been 
used successfully as a tumor-targeting ligand 
for several drug-delivery systems.
The entrapment of TRF in transferrin-bear-
ing vesicles significantly improved TRF uptake 
by at least threefold in A431 epidermoid car-
cinoma, A2780 ovarian carcinoma and T98G 
glioma compared with TRF solution [19]. 
Consequently, it led to more than a 100-fold 
improvement in cytotoxicity in the three 
tested cell lines compared with TRF solution. 
In vivo, the intravenous administration of TRF 
entrapped in transferrin-bearing vesicles led to 
tumor regression and improvement of animal 
survival in nude mice bearing sub cutaneous 
A431 tumors, in contrast to that observed with 
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controls [19]. At the end of the experiment, the 
extended survival of the mice treated with tar-
geted vesicles, control vesicles and free drug was 
19, 12 and 2 days, respectively, compared with 
untreated mice. The most striking effects of TRF 
entrapped in targeted vesicles were the ability of 
the drug to induce tumor regression within only 
24 h and the powerful tumor regression observed 
within 10 days. These had good tolerability of the 
treatment by the mice. This work corresponded to 
the first preparation of a tumor-targeted delivery 
system able to encapsulate tocotrienol. 
In our follow-up work with transferrin-bearing 
vesicles, we wanted to enhance and prolong the 
therapeutic effect of tocotrienol by entrapping 
this lipophilic drug in multilamellar, rather than 
unilamellar, vesicles, with the aim of improv-
ing drug loading within the lipidic membranes 
and therefore enhancing the therapeutic effi-
cacy of this system. As previously observed with 
our Solulan-based delivery system, transferrin-
bearing, tocopheryl-based multilamellar vesicles 
entrapping tocotrienol were able to improve the 
drug uptake by cancer cells overexpressing trans-
ferrin receptors, namely A431, T98G and B16-
F10 melanoma [20]. This resulted in an enhanced 
antiproliferative efficacy in vitro, reaching a max-
imum of 72-fold improvement for A431 cells, 
compared with the free drug. 
In vivo results were improved compared with 
those observed when using our previous delivery 
system. The intravenous administration of this 
novel tocotrienol formulation led to complete 
tumor eradication for 40% of B16-F10 tumors 
and 20% of A431 tumors [20]. The tumor regres-
sion appeared to follow a different pattern to that 
previously observed: the inter-individual variabil-
ity in the response to treatment was more pro-
nounced in this study, but the overall therapeu-
tic effect was more pronounced. This might be 
due to the involvement of different mechanisms 
of action of tocotrienol and is currently being 
further investigated. 
Animal survival was improved by more than 
20 days compared with controls, for the two 
tumor models tested. These therapeutic effects 
potentially make transferrin-bearing vesicles 
entrapping tocotrienol a highly promising thera-
peutic system as part of an anticancer therapeutic 
strategy [20]. 
Conclusion
The major obstacles for the development of tocot-
rienol as a successful anticancer drug are the poor 
bioavailability of the drug as well as its inability 
to specifically reach tumors at therapeutic con-
centrations after intravenous administration. 
Several methods for overcoming these problems 
are currently under investigation and have already 
led to significant improvement in tocotrienol 
bioavailability following oral administration. 
The entrapment of tocotrienol within tumor-
targeted delivery systems demonstrated its effec-
tiveness in vivo. We have recently demonstrated for 
the first time that a novel tocotrienol formulation 
can lead to complete tumor suppression after intra-
venous administration. Tocotrienol entrapped in 
transferrin-bearing vesicles led to complete tumor 
suppression for 40% of B16-F10 tumors and 20% 
of A431 tumors, with long-term survival of the 
animals. By contrast, 100% of the tumors treated 
with tocotrienol solution or left untreated were 
growing for both the tested tumors. 
These findings suggest that tumor-targeted 
tocotrienol could ultimately become a promising 
therapeutic tool in the treatment of cancer.
Future perspective 
While a large amount of research into tocotrienol 
has been focused on the elucidation of the numer-
ous and extremely diverse mechanisms of action 
implicated in the anticancer effects of tocotrienol, 
little has been done regarding the tumor-specific 
delivery of this drug in vivo. It is hoped that the 
promising results obtained when entrapping 
tocotrienol within these tumor-targeted delivery 
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systems will lead to the development of this field 
of research, in order to reveal the full anticancer 
potential of this drug. To date, no exact mecha-
nism has been identified as to how tocotrienol 
works. It will therefore be extremely important to 
precisely understand how tocotrienol functions, in 
order to be able to enhance and maintain its thera-
peutic action against cancer. Such understanding 
will be paramount to ultimately test this novel 
agent in preclinical and clinical settings. 
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